Cogent Biosciences, Inc. COGT
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing small-molecule precision therapies for genetically defined diseases. It focuses on modulating the tumor microenvironment, particularly through inhibitors targeting colony-stimulating factor 1 receptor (CSF1R), a regulator of …
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees258
TickerCOGT
Statistics
Market Cap$5.68B
Revenue (TTM)—
Net Income-$328.9M
Net Margin—
EPS$-2.16
P/E-15.96
P/S—
P/B10.26
EV/EBITDA-13.35
ROE-85.7%
Dividend Yield—
Price$33.26
Data: Twelve Data · Revenue = mcap / P/S